Wearable monitoring of positive and negative myoclonus in progressive myoclonic epilepsy type 1.

To develop and test wearable monitoring of surface electromyography and motion for detection and quantification of positive and negative myoclonus in patients with progressive myoclonic epilepsy type 1 (EPM1). Surface electromyography and three-dimensional acceleration were measured from 23 EPM1 patients from the biceps brachii (BB) of the dominant and the extensor digitorum communis (EDC) of the non-dominant arm for 48 hours. The patients self-reported the degree of myoclonus in a diary once an hour. Severity of myoclonus with action was evaluated by using video-recorded Unified Myoclonus Rating Scale (UMRS). Correlations of monitored parameters were quantified with the UMRS scores and the self-reported degrees of myoclonus. The monitoring-based myoclonus index correlated significantly (p < 0.001) with the UMRS scores (ρ = 0.883 for BB and ρ = 0.823 for EDC) and with the self-reported myoclonus degrees (ρ = 0.483 for BB and ρ = 0.443 for EDC). Ten patients were assessed as probably having negative myoclonus in UMRS, while our algorithm detected that in twelve patients. Wearable monitoring was able to detect both positive and negative myoclonus in EPM1 patients. Our method is suitable for quantifying objective, real-life treatment effects at home and progression of myoclonus.

Informations de copyright

Copyright © 2021 International Federation of Clinical Neurophysiology. Published by Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: S.M.R. is a co-founder in Adamant Health Ltd that develops EMG-based analysis software. J.H. Declarations of interest: none. K.S. Declarations of interest: none. L.S. Declarations of interest: none. P.A.K. is a co-founder in Adamant Health Ltd. E.M. Declarations of interest: none. R.K. is a medical advisor of Adamant Health Ltd. RK has received grants from the Academy of Finland and Saastamoinen Foundation, speaker’s honoraria from Eisai, Omamedica, Orion, Sandoz, Sanofi and UCB and honoraria for membership of the advisory boards/consultation of Eisai, Marinus Pharmaceuticals, Orion and UCB.